^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | SHP099 (PTPN11 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
Excerpt:
We next evaluated whether SHP099 would be efficacious in KRAS-mutant human tumor xenograft models. In line with the in vitro 3D findings, SHP099, dosed at 100 mg/kg daily, was efficacious in the MIA PaCa-2 model, with equivalent response to trametinib...tumor growth inhibition was observed in all other KRAS-mutant models tested...
DOI:
10.1158/1535-7163.MCT-19-0170
